Artemis Therapeutics, Inc. (ATMS) financial statements (2022 and earlier)

Company profile

Business Address 18 EAST 16TH STREET
NEW YORK, NY 10003
State of Incorp. DE
Fiscal Year End December 31
SIC 289 - Miscellaneous Chemical Products (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1127525907
Cash and cash equivalents1127525907
Other undisclosed current assets61020205865
Total current assets:7112227583972
Noncurrent Assets
TOTAL ASSETS:7112227583972
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3072461571615358
Accrued liabilities3072461571615358
Debt30     
Derivative instruments and hedges, liabilities   163  
Due to related parties166110    
Total current liabilities:5033561573245358
Noncurrent Liabilities
Liabilities, other than long-term debt  103   
Due to related parties  103   
Other undisclosed noncurrent liabilities    428 
Total noncurrent liabilities:  103 428 
Total liabilities:50335626032448158
Stockholders' equity
Stockholders' equity attributable to parent(496)(345)(238)(297)102914
Common stock52525252522,887
Additional paid in capital1,9371,9211,9071,5711,457(1,709)
Accumulated deficit(2,485)(2,318)(2,197)(1,920)(1,407)(264)
Total stockholders' equity:(496)(345)(238)(297)102914
TOTAL LIABILITIES AND EQUITY:7112227583972

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Operating expenses(154)(167)(168)(772)(1,039) 
Operating loss:(154)(167)(168)(772)(1,039) 
Nonoperating income (expense)(13)(7)(6)259(104) 
Investment income, nonoperating  (6)259  
Other nonoperating expense    (104) 
Loss from continuing operations before income taxes:(167)(174)(174)(513)(1,143) 
Income tax benefit 5353   
Net loss attributable to parent:(167)(121)(121)(513)(1,143) 
Preferred stock dividends and other adjustments25(18)(18)(77)(171) 
Other undisclosed net income available to common stockholders, basic2843636154342 
Net income (loss) available to common stockholders, diluted:142(103)(103)(436)(972) 

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(167)(121)(121)(513)(1,143) 
Comprehensive loss, net of tax, attributable to parent:(167)(121)(121)(513)(1,143) 

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: